Teva Pharmaceutical Industries Ltd. has announced that it would purchase Allergan PLC’s generic pharmaceuticals distributor for $500 million, just a day after Teva closed its much larger deal to buy Allergan’s generics business.
Teva is buying Allergan’s Anda Inc., the fourth-largest distributor of generic pharmaceuticals in the U.S.
Anda distributes drugs from more than 300 manufacturers to pharmacies across the U.S. and in 2016 Anda is expected to generate more than $1 billion in third-party net revenue.
As part of the deal, Teva will acquire distribution centers in Mississippi, Florida, and Ohio. Anda will operate as a stand-alone business. The deal is subject to regulatory approval and other closing conditions and is expected to close in the second half of the year.
Full Content: The Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
EU’s Incoming Competition Head Pushes for Policy Shift to Support ‘European Champions
Sep 19, 2024 by
CPI
Google Challenges $217 Million Legal Fee Demand in Privacy Case
Sep 19, 2024 by
CPI
EU Moves to Enforce Apple’s Compliance with New Market Rules
Sep 19, 2024 by
CPI
California Attorney General Bonta Stands Firm Against Albertsons-Kroger Merger
Sep 19, 2024 by
CPI
New FTC Report Highlights Privacy Risks in Social Media Data Use
Sep 19, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Canada & Mexico
Sep 3, 2024 by
CPI
Competitive Convergence: Mexico’s 30-Year Quest for Antitrust Parity with its Northern Neighbor
Sep 3, 2024 by
Francisco Javier Núñez Melgoza
Competition and Digital Markets in North America: A Comparative Study of Antitrust Investigations in Mexico and the United States
Sep 3, 2024 by
Julio Garcia
Recent Antitrust Development in Mexico: COFECE’s Preliminary Report on Amazon and Mercado Libre
Sep 3, 2024 by
Alejandra Palacios Prieto
The Cost of Making COFECE Disappear
Sep 3, 2024 by
Mateo Fernández